Clinical Trial

Study to Evaluate the Impact of a Targeted Lipid Optimization Program on LDL-C Control in At-risk Adult Patients With Dyslipidemia

Study acronym: OPTIMA
Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
This study is an open label, randomized, prospective, type I hybrid effectiveness- implementation, pragmatic clinical trial to evaluate the impact of a targeted lipid optimization program on LDL-C control in participants with dyslipidemia who are at high risk or very high risk of cardiovascular events.
Protocol Amendment History 2 changes
notable Primary completion pushed: 2026-06-23 -> 2027-05-31 2026-05-05
minor Completion pushed: 2027-06-30 -> 2028-05-31 2026-05-05
Trial Details
NCT Number NCT07034690
Lead Sponsor Novartis Pharmaceuticals
Conditions Atherosclerotic Cardiovascular Disease
Enrollment 326 participants
Start Date 2025-11-26
Primary Completion 2027-05-31 (estimated)
Study Completion 2028-05-31 (estimated)
Updated on ClinicalTrials.gov 2026-05-04